Assessing lead time bias due to mammography screening on estimates of loss in life expectancy.

ABSTRACT:

Background

An increasingly popular measure for summarising cancer prognosis is the loss in life expectancy (LLE), i.e. the reduction in life expectancy following a cancer diagnosis. The proportion of life lost (PLL) can also be derived, improving comparability across age groups as LLE is highly age-dependent. LLE and PLL are often used to assess the impact of cancer over the remaining lifespan and across groups (e.g. socioeconomic groups). However, in the presence of screening, it is unclear whether part of the differences across population groups could be attributed to lead time bias. Lead time is the extra time added due to early diagnosis, that is, the time from tumour detection through screening to the time that cancer would have been diagnosed symptomatically. It leads to arti

SUBMITTER: Syriopoulou E 

PROVIDER: S-EPMC8867879 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature